Pfizer Prunes Its Pipeline And Creates A Stockpile Of Compounds For Deals
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer's latest pipeline refinement shows the drug maker is more than willing to stick with its professed "invest to win" core therapeutic areas after acquiring Wyeth, but the pharma giant is, nonetheless, hedging its bets by keeping some compounds from other areas for the sake of diversity